Bridgeway Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Bridgeway Capital Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-80,900	Closed	-$84K	–	1451
2019 Q1	$84K	Sell	80,900 -50,000	-38%	-$40.7K	﹤0.01%	1292
2018 Q4	$98K	Hold	130,900	–	–	﹤0.01%	1309
2018 Q3	$278K	Hold	130,900	–	–	﹤0.01%	1266
2018 Q2	$302K	Buy	130,900 +50,000	+62%	+$146K	﹤0.01%	1249
2018 Q1	$257K	Hold	80,900	–	–	﹤0.01%	1234
2017 Q4	$332K	Sell	80,900 -8,000	-9%	-$34.8K	﹤0.01%	1192
2017 Q3	$402K	Buy	+88,900	New	+$360K	﹤0.01%	1144

Bridgeway Capital Management's OMED Position: Q2 2019 in Review

Bridgeway Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 80,900 shares — an estimated $84K sold.

Bridgeway Capital Management first reported a position in OMED in Q3 2017 and held it in 7 quarters. The position peaked at $402K in Q3 2017. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

Bridgeway Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 80,900 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $84K.
Bridgeway Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2017 and held it in 7 quarters.
Bridgeway Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $402K in Q3 2017.
0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.